|Videos|January 29, 2021
Third and Subsequent Line Options for Multiple Myeloma
Advertisement
Experts in multiple myeloma discuss third-line and subsequent options for treating multiple myeloma, and BCMA-targeted approaches presented at the ASH 2020 Virtual Meeting.
Data from the following presentations are discussed:
CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma. (Madduri, ASH 2020 Abstract 177)
Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes. (Alsina, ASH 2020 Abstract130)
Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma. (Mailankody, ASH 2020 Abstract129)
Advertisement
Related to this article
A new life-years-saved methodology found blood cancer treatments saved million years of life since 1949, with future gains reliant on funding and access.
Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Etentamig improved ORR and PFS vs standard therapies in triple-class exposed relapsed/refractory multiple myeloma.
Uma Borate, MBBS, MS, discusses data for different azacitidine and venetoclax schedules from the Beat AML master clinical trial.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
The selective ROCK2 inhibitor TDI01 generated organ-wide responses in previously treated moderate-to-severe chronic graft-versus-host disease, with the 400-mg dose performing best.
Advertisement
Advertisement
Trending on OncLive
1
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
2
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
3
Etentamig Meets PFS, ORR Primary End Points in Triple-Class Exposed R/R Myeloma
4
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
5